Skip to Main Content

Paper Details

GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro.
Signal Transduct Target Ther
7
2020
Author NameAffiliation
Wonhwa LeeAging Research Center, Korea Research Institute of Bioscience and Biotechnology
  • 1 - 1

Datasets

Release 1.2